ImmunOs Gets Cash Injection To Advance Potential First-In-Class Cancer Agent

Swiss Biotech Banks $74m

 
• By Kevin Grogan
  
US dollars
The funds will go towards development of ImmunOs’s lead program, IOS-1002 through Phase II trials. • Source: Archive

More from Business

More from Scrip